Unmet Needs in Preventing Adverse Drug-Drug Interactions

Clinical Advances in Hematology & Oncology August 2013, Volume 11, Issue 8 Mark J. Ratain, MD Leon O. Jacobson Professor of Medicine, Director, Center for Personalized […]

Potential Anticancer Benefits of Peptide Vaccines

Clinical Advances in Hematology & Oncology July 2013, Volume 11, Issue 7 Yusuke Nakamura, MD, PhD Professor of Medicine, Section of Hematology/Oncology, Professor of Surgery, Deputy Director, Center for […]

New Targets for Hematologic Malignancies

Clinical Advances in Hematology & Oncology June 2013, Volume 11, Issue 6 James Bradner, MD Assistant Professor, Department of Medicine, Harvard Medical School, Instructor in Medicine, Hematologic Neoplasia/Malignancies, Dana-Farber Cancer […]

Accounting for Tumor Heterogeneity in the Development of Predictive Biomarkers

Clinical Advances in Hematology & Oncology May 2013, Volume 11, Issue 5 Lillian L. Siu, MD, FRCPC Professor, University of Toronto, Cancer Care Ontario Research Chair, Experimental Therapeutics, Medical […]

Developing Drugs for Pediatric Malignancies

Clinical Advances in Hematology & Oncology April 2013, Volume 11, Issue 4 Peter C. Adamson, MD Chair, Children’s Oncology Group, Chief, Division of Clinical Pharmacology & Therapeutics, The […]

Update on CYP2D6 and Tamoxifen

Clinical Advances in Hematology & Oncology March 2013, Volume 11, Issue 3 Matthew P. Goetz, MD Consultant, Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota H&O What […]

Generic Sirolimus: A Future Opportunity to Decrease the Cost of Oncology Care?

Clinical Advances in Hematology & Oncology February 2013, Volume 11, Issue 2 Laurence H. Baker, DO Collegiate Professor, Cancer Developmental Therapeutics, Professor, Internal Medicine and Pharmacology, University of […]

Tivozanib in Renal Cell Carcinoma

Robert Figlin, MD, FACP Steven Spielberg Family Chair in Hematology-Oncology, Professor of Medicine and Biomedical Sciences, Chair, Division of Hematology Oncology, Deputy Director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los […]

ROS1-Targeted Therapy in Non–Small Cell Lung Cancer

Clinical Advances in Hematology & Oncology December 2012, Volume 10, Issue 12 H&O What is ROS1, and what is its mechanism of action? LS ROS1 is […]

Emerging Therapies in Melanoma

Clinical Advances in Hematology & Oncology November 2012, Volume 10, Issue 11 H&O What are the current outcomes in melanoma, and how are the data evolving? […]

PD-1–Targeted Immunotherapy: Recent Clinical Findings

Julie R. Brahmer, MD Associate Professor of Medical Oncology Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore, Maryland H&O What is known about the role […]

Scarcity of Vital Oncology Drugs: Finding Long-Term Solutions

Richard L. Schilsky, MD Immediate Past Chair Government Relations Committee, ASCO Professor of Medicine Chief, Section of Hematology-Oncology The University of Chicago Medicine Chicago, Illinois H&O […]

Using Ligands to Target Cancer Cells

Omid C. Farokhzad, MD Associate Professor of Anesthesia Harvard Medical School Director, Laboratory of Nanomedicine and Biomaterials Brigham and Women’s Hospital Boston, Massachusetts H&O What are […]

Clinical Applications of Next-Generation Sequencing

Michiaki Kubo, MD, PhD Acting Director RIKEN Center for Genomic Medicine Yokohama, Kanagawa Japan H&O What is next-generation sequencing (NGS)? MK NGS (also known as second-generation […]

Importance of Food Effects for Oral Oncology Drugs

Mark J. Ratain, MD Leon O. Jacobson Professor of Medicine Director, Center for Personalized Therapeutics Associate Director for Clinical Sciences Comprehensive Cancer Center The University of […]

PARP Inhibitors

Ruth Plummer, MA, BMBCh, DPhil, MD, FRCP Professor of Experimental Cancer Medicine Northern Institute for Cancer Research Newcastle University Newcastle upon Tyne, United Kingdom H&O What […]

New Approaches to Thyroid Cancer

Ezra E. Cohen, MD Associate Professor of Medicine Associate Director for Education University of Chicago Comprehensive Cancer Center Chicago, Illinois H&O How common is thyroid cancer, […]

Abiraterone: Current and FutureUse in Prostate Cancer

Charles J. Ryan, MD Associate Professor of Medicine and Urology Program Leader, Genitourinary Medical Oncology UCSF Helen Diller Family Comprehensive Cancer San Francisco, California H&O What […]

The Generic Drug Shortage

George Tidmarsh, MD, PhD Citizen’s Oncology Foundation Consulting Associate Professor of Pediatrics/Neonatology Stanford University School of Medicine Stanford, California H&O What are some of the issues […]

Harnessing the Immune Response

Thomas Gajewski, MD, PhD Professor, Department of Pathology and Department of Medicine Section of Hematology/Oncology Chicago, Illinois H&O hat is immunotherapy? TG he idea behind immunotherapy is to […]